Health Technology Assessment: informed by science or in the service of politics?

Patrícia Coelho de Soárez

Universidade São Paulo. Faculdade de Medicina. Departamento de Medicina Preventiva. São Paulo, SP, Brasil

ABSTRACT

The youth of Health Technology Assessment (HTA), as an institutional policy at the national level, signals the need to reflect on how its implementation took place under the perspective of its insertion in health policy and the scientific field. At the end of its first decade, these questions arise: has HTA translated into a health policy informed by science? Has its scientific foundation been used in the service of politics? To understand this political process, we apply the multiple-streams framework formulated by John Kingdon. The use of science to inform policy and the political use of science present themselves in an unstable balance. The survival of this policy will depend not only on science but on the art of orchestrating the interests of various agents so that HTA becomes a health policy for strengthening and sustainability of SUS.

DESCRIPTORS: Biomedical Technology Assessment. Health Technology Assessment. Science, Technology, and Health Innovation Management. National Science, Technology, and Innovation Policy. Science, Technology, and Society.
INTRODUCTION

The National Commission for Technology Incorporation in the Unified Health System (CONITEC) has become the centerpiece of the field of Health Technology Assessment (HTA) in Brazil. Its normative acts and official speech reiterate the importance of preparing technical reports based on scientific evidence, economic evaluation, and analysis of the impact of technologies adoption and the analysis of documents by deliberative processes. All instances of the Unified Health System (SUS) must share these processes. Also, they must be widely disseminated in society, allowing social participation in the decision-making process for technologies adoption into the SUS.

As an institutional policy at the national level, the HTA youth signals the need for a reflection on how its implementation occurred: from the perspective of its insertion in the health policy in general, and conversely, under the scientific field, which produced the essential science and technique for this institutionalization. At the end of its first decade, these questions arise: has HTA translated into a health policy informed by science? Was its scientific foundation used in the service of politics?

HTA Policy Formulation and Implementation Process

To understand this political process, the multiple-streams framework formulated by John Kingdon proves convenient. This theory argues that the entry of a new problem on the government’s agenda requires the confluence of three independent streams that cross the decision structures: the problem stream, the policy stream, and the political stream. The problem stream and the policy stream contain, respectively, issues that require public attention and ideas and technical proposals for solving the problems. The politics stream comprises political transitions and social pressure. When the three streams come together, windows of opportunity emerge, and governments decide to act.

In the case of HTA, the judicialization of public health was recognized as a fact whose problematic repercussions strengthened arguments in favor of implementing a policy that sought to resolve it. In 2005, the “judicialization epidemic” began: many lawsuits against the Brazilian Ministry of Health (MS), whose climax culminated in a public hearing on the judicialization of health within the SUS, convened by the President of the Supreme Court in 2009.

Since the 1990s, HTA was already a topic discussed by MS technical staff, but its relevance was not sufficiently recognized to be translated into actions and practices. In 2003, the administrative reform carried out in the MS suggested attention to strategic inputs, scientific and technological development, with the institution of the Secretariat of Science, Technology, and Strategic Inputs (SCTIE).

In the following year, society groups interested in the topic began to design possible alternatives, starting the policy stream. During the 2nd National Conference on Science, Technology, and Innovation in Health, the HTA was recognized as a strategic instrument to support technology management in health. For the first time, a specific policy in this field is proposed, resulting in the constitution of the Commission for Proposal Preparation for the National Policy on Health Technology Management (PNGTS) in 2005. In 2006, the MS created the Commission on Technology Incorporation (CITEC), the first body responsible for managing the process of incorporating technologies and supporting decision processes in SUS. The standards suggested by Kingdon were present: technical reliability, acceptability, and compatibility with current values in society at that time.

As for the politics stream, that was a favorable moment for the implementation of public policies, since in 2007, both the Secretary of Science, Technology and Strategic Inputs, as the Minister of Health, supported the idea of a policy based on scientific rationality to guide the technologies adoption into the SUS. The policy formulation process was able to advance
as the values and interests that guided the policy, and the political values and interests coincided. It culminated in the publication of the PNGTS in 20107.

Then followed a political move to structure a body responsible for adopting health technologies into the SUS. The unlikely combination of two almost antagonistic bills, 338/2007 and 219/2007, gave rise to Federal Law 12401/2011, which created CONITEC and determined that the SUS would only provide treatments included into public policies8.

The integration of the three streams (problem, policy, and politics) opened the window of opportunity for the creation of CONITEC, which instituted the formal role of the HTA in the decision-making processes of the SUS. CONITEC managed to implement in a short period the steps of the HTA process – the adoption stream, the rituals in the expanded composition plenary, the deadlines for analysis and recommendation, the public consultation, and the availability of recommendation reports. From January 2012 to September 2020, of the 717 requests for adoption of technologies received, 558 (78%) received a final recommendation from CONITEC9.

Concerning the scientific field, CONITEC’s recommendations are under critical analyses within the scope of scientific and technical quality in light of what the law dictates. The arguments focus on evaluating the quality and consistency of the recommendation reports and the transparency of the plenary’s deliberative process, including investigating the actors involved and the basis for their choices. The lack of publicity by the institutions responsible for preparing the reports has also been the target of criticism10,11.

From the perspective of political agents directly interested in adopting particular technologies, criticisms on the decisions are frequent, moreover, on what is considered a delay in adopting technologies presented as essential for patients with specific diseases. Thus, a questioning arises concerning the legitimacy of the policy of HTA as a whole.

Two main risks may have occurred in CONITEC’s HTA process: the risk of bias and the risk of incompleteness. The bias risk materializes when a distorted image of the evaluated technologies’ properties or value appears due to gaps in the available evidence or due to evidence interpretation or synthesis12. The process of incorporating Nusinersena, the most expensive drug product ever incorporated into the SUS, exemplifies this risk of bias. A flexibilization of the rite not supported by the available scientific evidence was established11.

As for the risk of incompleteness, specific technology evaluation criteria are neglected or not sufficiently recognized. This was the case of the recommendation to adopt six medicines into the SUS without registration with the Brazilian Health Regulatory Agency (ANVISA), i.e., without an assessment of their safety and efficacy13. Moreover, the risk of incompleteness in the incipient use of economic evaluations in recommendation reports was present. In these cases, eighty-eight (87.1%) technologies received a favorable recommendation for adoption without a full economic evaluation with the incremental cost-effectiveness ratio estimate10.

Development of the Scientific Field in Brazil

The institutionalization of the “evidence-based/informed” policy was possible due to the training of human resources and the formation of research networks strongly stimulated and financed by the Ministry of Health. The country formed a broad group of experts on the basic concepts and methods used in HTA studies14 and also an epistemic community15, or a scientific field, in a sense given by Bordieu15,16. There are dominant actors responsible for the rules of the field, for the development of national methodological guidelines, and for conducting the studies that instrumentalised CITEC and CONITEC. They dispute the legitimacy to participate in policies implementation and research funding, strongly directed by the MS.

Some of the seminal epistemic actors were academics and participated in government acting as critical catalysts for HTA. The influence of this initial group of specialists on
decision-makers diminished with the expansion and diversification of new areas added to
the field. The internal dynamics of this group reveals a fragile cohesion, a product of the
diversity of fields of origin or activity (Public Health, clinical area, pharmacy, economics)
of these professionals.

Human resources training is necessary to face the current challenges of evaluating
technological innovations, for example, for rare diseases\textsuperscript{17,18} and to deal with future
challenges related to the expansion of precision medicine (PM) in the next decade\textsuperscript{19}. An
enlarged group of researchers trained in traditional modeling approaches, such as Markov
models, has not yet been consolidated. The challenge of moving towards modeling with
dynamic simulation capable of capturing the individual care trajectories of PM technologies
is already pressing. New methods of economic evaluation of PM will be needed to deal with
this complexity of cascading decisions reflected in the multiple treatment trajectories
to make these methods result in significant information to support decisions in health
policies\textsuperscript{19}.

The high cost of PM technologies can exacerbate health inequalities and jeopardize
the sustainability of their systems, especially in low- and middle-income countries. The
evaluation of these technological innovations will require new technical knowledge and
possibly another process in the HTA bodies, given the pace of innovation and the regularity
of updating algorithms and applications\textsuperscript{10}.

**Perspectives on the Past and the Present to Reflect the Future of HTA**

The formulation of the PNGTS took place between 2004 and 2010, a moment of expansion
of social protection and affirmative action policies. The creation of CONITEC in 2011
crystallized the institutionalization of HTA in the SUS. HTA implementation took place
between 2013 and 2018, a turbulent period of democratic regression, continuous institutional
degradation, and economic crisis, especially marked by 2016, the year of the democratic
rupture related to President Dilma Rousseff’s impeachment and the extinction of all
secretariats and ministries linked to the expansion of rights or distributive policies\textsuperscript{21}.

The establishment of a national HTA body, such as CONITEC, is a difficult task that requires
many resources and a period of maturity and political commitment to become effective and
sustainable\textsuperscript{22}. Since 2016, CONITEC has lost its political strength and faced destabilization
strategies, with essential replacements in its technical staff. Also, the veiled skepticism
about policies based on scientific evidence became an explicit scientific denial after the
2018 election\textsuperscript{23}. A clear example of this position was the current government’s decision to
zero the import tax rate for Zolgensma, the most expensive drug product globally – whose
dose costs R$ 12 million – in July 2020, when the drug product was yet unregistered with
ANVISA.

Answering the initial questions, we can say that there is a precarious balance between the
use of science to inform policy and the political use of science. HTA policy has sought to be
informed by science, but technical-scientific gaps must be addressed to make this process
based on scientific evidence. It has been used in the service of politics and is currently at
risk for not being valued in current political discourse.

The survival of this policy will depend not only on science, i.e., on the strengthening of
scientific and technical quality, but above all on the art of orchestrating the interests of
the political and judicial systems, and the epistemic community and civil society, to favor
insertion of HTA in a health policy that strengthens the SUS.

Therefore, we expect the reversal of this pendular movement of counter-democracy and
advocate that the new HTA ceases to be a government policy and establishes itself as
a health and social policy capable of guiding the increasingly complex SUS decision-
making processes. We hope that HTA can offer a transparent, legitimate, and fair process,
contributing to access to technological innovations following the population’s needs and the
social value of these technologies, in compliance with the principles of universality, equity, and integrity. Thus, SUS safety, quality, and efficiency standards can be guaranteed, and its sustainability assured.

REFERENCES

1. Capucho HC, Salomon FCR, Vidal AT, Louly PG, Santos VCC, Petramale CA. Incorporação de tecnologias em saúde no Brasil: novo modelo para o Sistema Único de Saúde. BIS Bol Inst Saúde. 2012;13(13):215-22.

2. Kingdon JA. Agendas, alternatives, and public policies. 2. ed. New York: Longman; 2003. (Longman Classics in Political Science).

3. Walt G, Shiffman J, Schneider H, Murray SF, Brugha R, Gilson L. ‘Doing’ health policy analysis: methodological and conceptual reflections and challenges. Health Policy Plan. 2008;23(5):308-17. https://doi.org/10.1093/heapoli/czn024

4. Machado TRC. Judicialização da saúde: analisando a audiência pública no Supremo Tribunal Federal. Rev Bioet. 2014;22(3):561-8. https://doi.org/10.1590/1983-80422014223039

5. Teixeira CF, Paim JS. A política de saúde no governo Lula e a dialética do menos pior. Saude Debate. 2005;29(71):268-83.

6. Ministério da Saúde BR), Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia. Avaliação de Tecnologias em Saúde: institucionalização das ações no Ministério da Saúde. Rev Saude Publica. 2006;40(4):743-7. https://doi.org/10.1590/S0034-891020060004000029

7. Ministério da Saúde (BR), Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Política Nacional de Gestão de Tecnologias em Saúde. Brasília, DF; 2010. (Série B. Textos Básicos em Saúde).

8. Yuha TY. Política nacional de gestão de tecnologias em saúde: um estudo de caso da Comissão Nacional de Incorporação de Tecnologias no SUS [tese]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2018.

9. Rede Raras -Observatório de Doenças Raras. Incorporação de tecnologias no Sistema Único de Saúde: painel de monitoramento das solicitações de incorporação de tecnologias em saúde protocoladas na Conitec. Brasília, DF; 2020 [cited 2020 Oct 8]. Available from: http://rederraras.unb.br/?p=360

10. Yuha TY, Novaes HMD, Soárez PC. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations. Health Res Policy Syst. 2018;16(1):40. https://doi.org/10.1186/s12961-018-0319-8

11. Caetano R, Hauegen RC, Osorio-de-Castro CGS. A incorporação do nusinersena no Sistema Único de Saúde: uma reflexão crítica sobre a institucionalização da avaliação de tecnologias em saúde no Brasil. Cad Saude Publica. 2019;35(8):e00099619. https://doi.org/10.1590/0102-311X00099619

12. Wilt GJ, Rüther A, Trowman R. Scientific Development of HTA-A proposal by the Health Technology Assessment International Scientific Development and Capacity Building Committee. Int J Technol Assess Health Care. 2019;35(4):263-5. https://doi.org/10.1017/S0266642319000539

13. Caetano R, Silva RM, Pedro EM, Oliveira IAG, Biz AN, Santana P. Incorporação de novos medicamentos pela Comissão Nacional de Incorporação de Tecnologias do SUS, 2012 a junho de 2016. CienCi Saude Coletiva. 2017;22(8):2513-25. https://doi.org/10.1590/1413-812320172228.02002017

14. Novaes HMD, Soárez PC. A Avaliação das Tecnologias em Saúde: origem, desenvolvimento e desafios atuais. Panorama internacional e Brasil. Cad Saude Publica. 2020;36(9):e00006820. https://doi.org/10.1590/0102-311X0006820

15. Haas PM. Introduction: epistemic communities and international policy coordination. Int Organ. 1992;46(1):1-35. https://doi.org/10.1017/S002081830001442

16. Cross MKD. Rethinking epistemic communities twenty years later. Rev Int Stud. 2013;39(1):137-60. https://doi.org/10.1017/S0260210512000034

17. Nestler-Parr S, Korchagina D, Tourmi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: report
of the ISPOR Rare Disease Special Interest Group. Value Health. 2018;21(5):493-500. https://doi.org/10.1016/j.jval.2018.03.004

18. Novaes HMD, Soárez PC. Doenças raras, drogas órfãs e as políticas para avaliação e incorporação de tecnologias nos sistemas de saúde. Sociologias. 2019;21(51):332-64. https://doi.org/10.1590/15174522-0215121

19. Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, et al. Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling. Value Health. 2020;23(5):566-73. https://doi.org/10.1016/j.jval.2020.01.016

20. Love-Koh J, Peel A, Rejon-Parrilla JC, Ennis K, Lovett R, Manca A, et al. The future of precision medicine: potential impacts for health technology assessment. Pharmacoeconomics. 2018;36(12):1439-51. https://doi.org/10.1007/s40273-018-0686-6

21. Avritzer L. O pêndulo da democracia no Brasil: uma análise da crise 2013-2018. Novos Estud CEBRAP. 2018;37(2):273-89. https://doi.org/10.25091/S01013300201800020006

22. Kristensen FB, Nielsen CP, Panteli D. Regulating the input - Health Technology Assessment. In: Busse R, Klazinga N, Panteli D, Quentin W, editors. Improving healthcare quality in Europe: characteristics, effectiveness and implementation of different strategies. Copenhagen (DK): European Observatory on Health Systems and Policies; 2019. Part I-6. (Health Policy Series).

23. Donadelli F. When evidence does not matter: the barriers to learning from science in two cases of environmental policy change in Brazil. Sci Public Policy. 2020;47(3):313-21. https://doi.org/10.1093/scipol/scaa006

Funding: Patrícia Coelho de Soareza is a researcher at the National Institute of Science and Technology (INCT) - Institute of Health Technology Assessment (IATS), of the National Council for Scientific and Technological Development (CNPq) (465518/2014-1).

Authors’ Contribution: Study design and planning: PCS. Data collection, analysis, and interpretation: PCS. Manuscript preparation or revision: PCS. Final version approval: PCS. Public responsibility for the content of the article: PCS.

Conflict of Interest: The author declares no conflict of interest.